Profound inhibition of antigen-specific T-cell effector functions by dasatinib.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Ralf WeichselRuth Seggewiss

Abstract

The dual BCR-ABL/SRC kinase inhibitor dasatinib entered the clinic for the treatment of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia. Because SRC kinases are known to play an important role in physiologic T-cell activation, we analyzed the immunobiological effects of dasatinib on T-cell function. The effect of dasatinib on multiple T-cell effector functions was examined at clinically relevant doses (1-100 nmol/L); the promiscuous tyrosine kinase inhibitor staurosporine was used as a comparator. Purified human CD3+ cells and virus-specific CD8+ T cells from healthy blood donors were studied directly ex vivo; antigen-specific effects were confirmed in defined T-cell clones. Functional outcomes included cytokine production (interleukin-2, IFN gamma, and tumor necrosis factor alpha), degranulation (CD107a/b mobilization), activation (CD69 up-regulation), proliferation (carboxyfluorescein diacetate succinimidyl ester dilution), apoptosis/necrosis induction, and signal transduction. Both dasatinib and staurosporine inhibited T-cell activation, proliferation, cytokine production, and degranulation in a dose-dependent manner. Mechanistically, this was mediated by the blockade of early signal transduction events and was...Continue Reading

References

Mar 11, 1998·Current Opinion in Immunology·A Hayday, L Geng
May 20, 1999·The Journal of Clinical Investigation·J DéchanetJ F Moreau
Apr 5, 2001·The New England Journal of Medicine·B J DrukerC L Sawyers
Mar 1, 2002·The New England Journal of Medicine·David G Savage, Karen H Antman
Oct 3, 2002·Nature Reviews. Immunology·Joseph A Trapani, Mark J Smyth
Apr 17, 2003·The Journal of Biological Chemistry·Sarah L HutchinsonAndrew K Sewell
Aug 28, 2003·Nature Immunology·Robert A Seder, Rafi Ahmed
Oct 29, 2003·Journal of Immunological Methods·Michael R BettsRichard A Koup
Jan 22, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Xue-Zhong YuClaudio Anasetti
Dec 14, 2005·European Journal of Haematology·Martin BornhäuserUNKNOWN Cooperative German Transplant Study Group
Jun 16, 2006·The New England Journal of Medicine·Moshe TalpazCharles L Sawyers
Sep 30, 2006·Cancer Immunology, Immunotherapy : CII·Jinfei ChenMichael Schmitt
Oct 25, 2006·Proceedings of the National Academy of Sciences of the United States of America·Kavita TewariM Suresh
Dec 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles ChuahAlwin Hwai Liang Loh
Jun 15, 2007·Experimental Hematology·Christoph LederHeinz Wiendl

❮ Previous
Next ❯

Citations

Jun 5, 2012·International Journal of Hematology·Peter Rohon
Aug 6, 2002·Immunology Letters·Baohui XuToru Takeuchi
Jun 30, 2009·Bone Marrow Transplantation·P GarlandD Marin
Feb 26, 2011·Leukemia·A HeineP Brossart
Feb 4, 2012·Nature Reviews. Drug Discovery·Lorenzo GalluzziGuido Kroemer
Nov 30, 2011·TheScientificWorldJournal·Jacopo OlivieriAttilio Olivieri
Aug 2, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jahan S KhaliliGregory Lizée
Dec 23, 2010·Immunotherapy·Yasuhiko NishiokaSaburo Sone
Sep 18, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Elisabetta AbruzzeseRoberto Latagliata
Jan 7, 2014·Current Hematologic Malignancy Reports·Mette IlanderSatu Mustjoki
Apr 25, 2012·International Journal of Hematology·Michael J WebbVernon J Louw
Mar 28, 2012·International Reviews of Immunology·Nicole J HorwoodLynett Danks
Dec 17, 2014·Leukemia & Lymphoma·Faruk ObutCelalettin Ustun
Nov 12, 2013·Critical Reviews in Oncology/hematology·Semra Paydas
Sep 12, 2009·European Journal of Clinical Investigation·C SillaberP Valent
Jun 7, 2011·Leukemia Research·Celalettin UstunCem Akin
Sep 30, 2009·Experimental Hematology·Cara K FraserJohn D Hayball
Jan 8, 2009·Immunology·Linda WooldridgeAndrew K Sewell
Oct 7, 2008·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Pratip K ChattopadhyayDavid A Price
Nov 20, 2008·British Journal of Haematology·Fei FeiMichael Schmitt
Jul 26, 2011·Cancer Science·Shunji TakahashiKiyohiko Hatake
Jul 6, 2010·European Journal of Clinical Investigation·Peter Valent
Oct 31, 2012·Hematological Oncology·Takayoshi UchiyamaMasuhiro Takahashi
Mar 16, 2012·International Journal of Cancer. Journal International Du Cancer·Nicole HassoldRuth Seggewiss-Bernhardt
Oct 10, 2013·International Journal of Cancer. Journal International Du Cancer·Ritika JainiVincent K Tuohy
Dec 20, 2013·Cancer Biology & Therapy·Zhi-Yuan QiuJian-Yong Li
Aug 2, 2014·Oncoimmunology·Anna KreutzmanSatu Mustjoki
Aug 27, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Partow KebriaeiRichard Champlin
Oct 22, 2008·Journal of Immunological Methods·Anna LissinaLinda Wooldridge

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis